About
This session covers the evolution of pharmacological treatments for migraines. Learn about the history and future of migraine medications, from ergots and triptans to the latest innovations such as gepants, CGRP antibodies, and Delta opioid receptor therapies. Discover how the latest routes of administration are transforming treatment options. 
Agenda
  • Ergots & Triptans - Presented by Professor Stephen Silberstein, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
  • Gepants & Anti-CGRP Antibodies - Presented by Professor Lars Edvinsson, University of Lund, Lund, Sweden
  • Delta Opioid Receptor System & Other (Potential) Future Therapies - Presented by Professor Amynah Pradhan, Washington University, St Louis, Missouri, USA
Presenters
1727277123-061ef4d1499adfdb
Dr. Stephen Shrewsbury
Principal at Shrewd Consulting LLC and previously Chief Medical Officer at Impel Pharmaceuticals and at MAP Pharmaceuticals, and editor of Migraine Pain Management
Stephen B. Shrewsbury, spent his first 13 years in UK clinical practice in primary care and pulmonary medicine, before joining Glaxo and accepting honorary clinical positions at both the Department of Child Health at Southampton University and then the Department of Allergy and Clinical Immunology at the National Heart and Lung Institute in London. In 2000, he moved to the US and led Glaxo’s inhaled fluticasone and Upper Respiratory Inflammatory Disorders programs before moving to the west coast to lead Chiron’s Inhaled Antibiotic Core Team. Steve has held the CMO position in several biotech companies including MAP Pharmaceuticals, Adamas Pharmaceuticals, AVI BioPharma (now Sarepta Therapeutics), Aquinox Pharmaceuticals, and lastly at Impel Pharmaceuticals where he led drug-device combination product programs delivering drugs to the upper nasal space, in migraine, acute agitation and Parkinson’s disease and now runs his Shrewd Consulting business. Dr. Shrewsbury qualified MB ChB in Medicine from The University of Liverpool, UK.
1727282598-86067c27f178a9b3
Dr. Stephen Silberstein
Professor, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
Professor of Neurology and Director of the Jefferson Headache Center at Thomas Jefferson University in Philadelphia, PA; one of the few academic headache centers in the country. Involved with migraine research and clinical trials. Author of over 500 peer-reviewed publications.

A Fellow of the American College of Physicians, the American Academy of Neurology, and the American Headache Society (AHS). Served the AHS as President, Treasurer, and Board of Directors member. He is the 2016 Lifetime Achievement Award recipient by AHS, the International Headache Society Lifetime Achievement Award 2023, and the Headache Cooperative of the Northeast Lifetime Achievement Award 2024. Chairman within the World Federation of Neurology and President of the Philadelphia Headache Society.

Dr. Silberstein is the senior editor of the 8th edition (and the upcoming 9th edition) of Wolff’s Headache and Other Head Pain, Associate Editor of Cephalalgia and CNS Drugs, and a present or prior member of the Editorial Board of Headache, Cephalalgia, Acta Neurologica Scandanavia, Journal of Neurology, Neurosurgery and Psychology, and Topics in Pain Management, Journal of Neurology, Neurosurgery and Psychology, and Topics in Pain Management.
1727277712-35903c2ed0065a58
Dr. Lars Edvinsson
Director and Founder, Glostrup Research Institute, Copenhagen University Hospital, Denmark; Professor in Internal Medicine, Faculty of Medicine, University Hospital SUS Lund, Sweden
Professor Lars Edvinsson is recognized as a leading expert in the field of vascular innervation and receptor regulation and his extensive research has been a major contributor to understanding roles of the coronary, cerebral and peripheral vasculature in health and diseases such as AMI, stroke and primary headaches. His research has founded the development of novel drugs for the treatment of neurovascular diseases (especially with his pioneering work on CGRP).
1727277921-adef908147266a1b
Dr. Amynah Pradhan
Director, Center for Clinical Pharmacology, and Professor, Washington University, St Louis, Missouri, USA
Amynah Pradhan, PhD, an award-winning neuroscientist, was appointed director of the Center for Clinical Pharmacology (CCP) in 2022. Dr. Pradhan joins the CCP from the Department of Psychiatry at the University of Illinois at Chicago, where she has been faculty since 2013 and associate professor with tenure since 2019. At UIC, Dr. Pradhan has also served as Director of the Graduate Program in Neuroscience since 2019.

As Center Director, Dr. Pradhan leads the strategic planning efforts for all research growth and development, provides mentorship for trainees and faculty, fosters a diverse and inclusive environment to stimulate new and exciting research endeavors, and continues to grow inter-institutional partnerships and collaborations as well as national recognition for the Center.
Register To Watch Recording
First Name*
Last Name*
Email Address*
Job Title*
Institution*
Country*
Contact Permission
We would like to keep you up-to-date with what's happening at Elsevier and tell you about our latest products and other services. We may email you about information we think you'll be interested in, including reminders about upcoming events.
For more information, please read our privacy policy
✓ If you do not wish to receive such information please tick the box to opt out of these emails.